Could heme-oxygenase-1 have a role in modulating the recipient immune response to embryonic stem cells?

Pluripotent human embryonic stem cells (hESCs) may provide a potential source of cellular therapies, but as allogeneic cells may require evading the recipient's immune response. Using an NIH-registry hESC line, it was found that undifferentiated hESCs induce a reduced proliferative response compared to PBMC and demonstrate that this diminished response correlates with the activity of heme oxygenase-1 (HO-1). Inhibition of HO-1 significantly increases T cell proliferation against hESC, indicating the potential suppression of these cells during transplantation of allogeneic hESC. These data suggest the hypothesis that HO-1 provides a mechanism for protecting hESCs in vivo.

[1]  A. Srivastava,et al.  Transplanted Embryonic Stem Cells Successfully Survive, Proliferate, and Migrate to Damaged Regions of the Mouse Brain , 2006, Stem cells.

[2]  C. Adin,et al.  Products of heme oxygenase and their potential therapeutic applications. , 2006, American journal of physiology. Renal physiology.

[3]  N. Benvenisty,et al.  Human Embryonic Stem Cells and Their Differentiated Derivatives Are Less Susceptible to Immune Rejection Than Adult Cells , 2006, Stem cells.

[4]  K. Wood,et al.  Transplanting stem cells: potential targets for immune attack. Modulating the immune response against embryonic stem cell transplantation. , 2005, Advanced drug delivery reviews.

[5]  I. Weissman,et al.  They are not stealthy in the heart: embryonic stem cells trigger cell infiltration, humoral and T-lymphocyte-based host immune response. , 2005, European journal of cardio-thoracic surgery : official journal of the European Association for Cardio-thoracic Surgery.

[6]  S. Remy,et al.  Heme oxygenase-1 expression inhibits dendritic cell maturation and proinflammatory function but conserves IL-10 expression. , 2005, Blood.

[7]  C. Scott,et al.  Chasing a cellular fountain of youth , 2005, Nature Biotechnology.

[8]  Wenda Gao,et al.  Donor treatment with carbon monoxide can yield islet allograft survival and tolerance. , 2005, Diabetes.

[9]  E. Hauben,et al.  Utilizing regulatory T cells to control alloreactivity. , 2005, Cytotherapy.

[10]  K. Boheler,et al.  Embryonic stem cells: prospects for developmental biology and cell therapy. , 2005, Physiological reviews.

[11]  P. Andrews,et al.  Human embryonic stem cells: Possibilities for human cell transplantation , 2005, Annals of medicine.

[12]  F. Bach,et al.  Biliverdin therapy protects rat livers from ischemia and reperfusion injury , 2004, Hepatology.

[13]  Li Li,et al.  Human Embryonic Stem Cells Possess Immune‐Privileged Properties , 2004, Stem cells.

[14]  D. V. van Bockstaele,et al.  Current challenges in human embryonic stem cell research: directed differentiation and transplantation tolerance. , 2004, Journal of biological regulators and homeostatic agents.

[15]  E. Holler,et al.  Induction of heme oxygenase-1 before conditioning results in improved survival and reduced graft-versus-host disease after experimental allogeneic bone marrow transplantation. , 2004, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

[16]  Young-Myeong Kim,et al.  Carbon Monoxide Produced by Heme Oxygenase-1 Suppresses T Cell Proliferation via Inhibition of IL-2 Production1 , 2004, The Journal of Immunology.

[17]  F. Bach,et al.  Biliverdin, a natural product of heme catabolism, induces tolerance to cardiac allografts , 2004, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[18]  F. Bach,et al.  Heme oxygenase‐1‐derived carbon monoxide protects hearts from transplant‐associated ischemia reperfusion injury , 2004, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[19]  S. Remy,et al.  Induction of long-term cardiac allograft survival by heme oxygenase-1 gene transfer , 2004, Gene Therapy.

[20]  A. Choi,et al.  Suppression of Inflammatory Cytokine Production by Carbon Monoxide Involves the JNK Pathway and AP-1* , 2003, Journal of Biological Chemistry.

[21]  F. Bach,et al.  Heme oxygenase-1: unleashing the protective properties of heme. , 2003, Trends in immunology.

[22]  M. Rao,et al.  Characterization and differentiation of human embryonic stem cells. , 2003, Cloning and stem cells.

[23]  Solomon H. Snyder,et al.  Biliverdin reductase: A major physiologic cytoprotectant , 2002, Proceedings of the National Academy of Sciences of the United States of America.

[24]  Maya Schuldiner,et al.  Characterization of the expression of MHC proteins in human embryonic stem cells , 2002, Proceedings of the National Academy of Sciences of the United States of America.

[25]  Chunhui Xu,et al.  Feeder-free growth of undifferentiated human embryonic stem cells , 2001, Nature Biotechnology.

[26]  F. Bach,et al.  Heme oxygenase-1 induction in islet cells results in protection from apoptosis and improved in vivo function after transplantation. , 2001, Diabetes.

[27]  A. Choi,et al.  Carbon Monoxide Generated by Heme Oxygenase 1 Suppresses Endothelial Cell Apoptosis , 2000, The Journal of experimental medicine.

[28]  J Zaky,et al.  Upregulation of heme oxygenase-1 protects genetically fat Zucker rat livers from ischemia/reperfusion injury. , 1999, The Journal of clinical investigation.

[29]  G. Drummond,et al.  Control of heme metabolism with synthetic metalloporphyrins. , 1986, The Journal of clinical investigation.